Holox, a Beijing-based developer of healthcare management software, has reportedly secured tens of millions of renminbi in a Series A+ financing round. The funds raised will be directed towards the research and development of new products and the globalization of the company’s operations.
Company Background and Pharmaceutical Safety Services
Founded in 2016, Holox has established a unique model of “digital SaaS + safety severe vertical services for the entire life and entire industry chain pharmaceutical safety industry.” The company specializes in providing drug vigilance and risk management services that cover the entire life cycle of pharmaceuticals, from clinical trials to post-market surveillance. Holox has launched four major SaaS platforms that cater to internationalized clinical pharmacovigilance, post-market pharmacovigilance, vaccine vigilance, and real-world research scenarios.
Holox’s Comprehensive SaaS Platform Offerings
The company’s four major SaaS platforms include Holox Clinical, Holox Pharma, Holox Vaccin, and Holox RWE. These platforms enable a comprehensive approach to pharmaceutical safety and efficacy across various stages of drug development and post-approval monitoring. Holox Clinical focuses on clinical pharmacovigilance, Holox Pharma on post-market pharmacovigilance, Holox Vaccin on vaccine surveillance, and Holox RWE on real-world research applications.
Global Expansion and Future Prospects
With the proceeds from the Series A+ financing, Holox is well-positioned to expand its product pipeline and enhance its global reach. The investment will support the company’s mission to provide cutting-edge software solutions that address the complex needs of the pharmaceutical industry, ensuring safety and compliance across the entire drug life cycle.-Fineline Info & Tech
